Hyperexpression of SCD1 is linked with a variety of metabolic disorders, like hypertriglyceridemia, and hence SCD1 inhibitors are attractive candidates to treat metabolic syndrome (Kamal et al., 2018). This evidence concerns the gene SCD and Other metabolic disease.